These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1718792)

  • 1. Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia.
    Serio M; Fiorelli G
    Mol Cell Endocrinol; 1991 Jun; 78(1-2):C77-81. PubMed ID: 1718792
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors.
    Gormley GJ
    J Cell Biochem Suppl; 1992; 16H():113-7. PubMed ID: 1283894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finasteride for benign prostatic hyperplasia.
    DuBeau CE
    N Engl J Med; 1993 Feb; 328(6):443. PubMed ID: 7678439
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
    Tempany CM; Partin AW; Zerhouni EA; Zinreich SJ; Walsh PC
    Prostate; 1993; 22(1):39-42. PubMed ID: 7678931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
    Beisland HO; Binkowitz B; Brekkan E; Ekman P; Kontturi M; Lehtonen T; Lundmo P; Pappas F; Round E; Shapiro D
    Eur Urol; 1992; 22(4):271-7. PubMed ID: 1283370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
    Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
    Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New options for patients with benign prostatic hyperplasia.
    Ellenberger B
    CMAJ; 1993 Feb; 148(4):543-7. PubMed ID: 7679313
    [No Abstract]   [Full Text] [Related]  

  • 13. Finasteride for benign prostatic hyperplasia.
    Holdcroft C
    Nurse Pract; 1993 Mar; 18(3):57-8. PubMed ID: 7681553
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of finasteride in men with benign prostatic hyperplasia.
    Walsh PC
    J Urol; 1993 Apr; 149(4):932-3. PubMed ID: 7681121
    [No Abstract]   [Full Text] [Related]  

  • 15. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
    Guess HA; Heyse JF; Gormley GJ
    Prostate; 1993; 22(1):31-7. PubMed ID: 7678930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia.
    Cohen SM; Taber KH; Malatesta PF; Shpungin J; Berman C; Carlin JR; Werrmann JG; Prahalada S; Bryan RN; Cordes EH
    Magn Reson Med; 1991 Sep; 21(1):55-70. PubMed ID: 1719333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
    Vermeulen A; Giagulli VA; De Schepper P; Buntinx A
    Eur Urol; 1991; 20 Suppl 1():82-6. PubMed ID: 1722168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New medication for the treatment of benign prostatic hyperplasia.
    Miller CA
    Geriatr Nurs; 1993; 14(2):111-2. PubMed ID: 7681420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.